NASDAQ:LYRA Lyra Therapeutics (LYRA) Stock Price, News & Analysis $7.00 -0.05 (-0.71%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$7.04 +0.04 (+0.50%) As of 08/29/2025 05:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lyra Therapeutics Stock (NASDAQ:LYRA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Lyra Therapeutics alerts:Sign Up Key Stats Today's Range$6.94▼$7.1550-Day Range$6.58▼$13.3852-Week Range$3.81▼$37.50Volume6,056 shsAverage Volume16,200 shsMarket Capitalization$11.48 millionP/E RatioN/ADividend YieldN/APrice Target$100.00Consensus RatingHold Company Overview Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts. Read More Lyra Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreLYRA MarketRank™: Lyra Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 442nd out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingLyra Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageLyra Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Lyra Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Lyra Therapeutics are expected to grow in the coming year, from ($0.93) to ($0.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lyra Therapeutics is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lyra Therapeutics is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLyra Therapeutics has a P/B Ratio of 7.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Lyra Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.95% of the float of Lyra Therapeutics has been sold short.Short Interest Ratio / Days to CoverLyra Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lyra Therapeutics has recently decreased by 8.62%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLyra Therapeutics does not currently pay a dividend.Dividend GrowthLyra Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.95% of the float of Lyra Therapeutics has been sold short.Short Interest Ratio / Days to CoverLyra Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lyra Therapeutics has recently decreased by 8.62%, indicating that investor sentiment is improving significantly. News and Social Media2.1 / 5News SentimentN/A News SentimentLyra Therapeutics has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.09 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Lyra Therapeutics this week, compared to 1 article on an average week.Search Interest4 people have searched for LYRA on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Lyra Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $20,039.00 in company stock.Percentage Held by InsidersOnly 3.25% of the stock of Lyra Therapeutics is held by insiders.Percentage Held by Institutions95.62% of the stock of Lyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lyra Therapeutics' insider trading history. Receive LYRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LYRA Stock News HeadlinesLyra Therapeutics Receives Nasdaq Deficiency LetterAugust 23, 2025 | msn.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Lyra Therapeutics (LYRA), Stoke Therapeutics (STOK) and Astria Therapeutics (ATXS)August 14, 2025 | theglobeandmail.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.August 31 at 2:00 AM | Porter & Company (Ad)Lyra Therapeutics Faces Manufacturing and Staffing Challenges Amid LYR-210 Production ShiftAugust 14, 2025 | tipranks.comLyra Therapeutics reports Q2 EPS ($5.51), consensus ($4.78)August 12, 2025 | msn.comLyra Therapeutics Posts 85% Q2 Loss DropAugust 12, 2025 | theglobeandmail.comLyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 12, 2025 | globenewswire.comLyra Therapeutics Board Chair Waksal Steps DownAugust 2, 2025 | marketwatch.comSee More Headlines LYRA Stock Analysis - Frequently Asked Questions How have LYRA shares performed this year? Lyra Therapeutics' stock was trading at $10.32 at the beginning of 2025. Since then, LYRA stock has decreased by 32.2% and is now trading at $7.00. How were Lyra Therapeutics' earnings last quarter? Lyra Therapeutics, Inc. (NASDAQ:LYRA) released its earnings results on Tuesday, August, 12th. The company reported ($5.51) EPS for the quarter, topping analysts' consensus estimates of ($5.79) by $0.28. The business had revenue of $0.29 million for the quarter, compared to the consensus estimate of $0.18 million. Lyra Therapeutics had a negative net margin of 5,043.64% and a negative trailing twelve-month return on equity of 404.56%. When did Lyra Therapeutics' stock split? Lyra Therapeutics shares reverse split before market open on Wednesday, May 28th 2025.A 1-50 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. When did Lyra Therapeutics IPO? Lyra Therapeutics (LYRA) raised $52 million in an initial public offering on Friday, May 1st 2020. The company issued 3,500,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and William Blair acted as the underwriters for the IPO and BTIG was co-manager. Who are Lyra Therapeutics' major shareholders? Lyra Therapeutics' top institutional investors include Perceptive Advisors LLC (15.56%), Bank of America Corp DE (1.74%) and Geode Capital Management LLC (0.69%). Insiders that own company stock include Maria Palasis, Jason Cavalier, Perceptive Advisors Llc, Nbvm Gp, Llc and Harlan Waksal. View institutional ownership trends. How do I buy shares of Lyra Therapeutics? Shares of LYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lyra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lyra Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD), ServiceNow (NOW) and Adobe (ADBE). Company Calendar Last Earnings8/12/2025Today8/30/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryMedical Equipment Current SymbolNASDAQ:LYRA CIK1327273 Webwww.lyratherapeutics.com Phone617-393-4600FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Price Target for Lyra Therapeutics$100.00 High Price Target$100.00 Low Price Target$100.00 Potential Upside/Downside+1,328.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($29.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$93.43 million Net Margins-5,043.64% Pretax Margin-5,041.17% Return on Equity-404.56% Return on Assets-60.06% Debt Debt-to-Equity RatioN/A Current Ratio2.78 Quick Ratio2.78 Sales & Book Value Annual Sales$1.53 million Price / Sales7.50 Cash FlowN/A Price / Cash FlowN/A Book Value$0.99 per share Price / Book7.07Miscellaneous Outstanding Shares1,640,000Free Float1,592,000Market Cap$11.48 million OptionableOptionable Beta0.16 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:LYRA) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.